123 related articles for article (PubMed ID: 38520957)
21. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
22. Genetic characteristics and treatment outcome in infants with KMT2A germline B-cell precursor acute lymphoblastic leukemia: Results of MLL-Baby protocol.
Popov A; Tsaur G; Permikin Z; Henze G; Verzhbitskaya T; Plekhanova O; Nokhrina E; Valochnik A; Sibiryakov P; Zerkalenkova E; Olshanskaya Y; Gindina T; Movchan L; Shorikov E; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
Pediatr Blood Cancer; 2023 Apr; 70(4):e30204. PubMed ID: 36715125
[TBL] [Abstract][Full Text] [Related]
23. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
[TBL] [Abstract][Full Text] [Related]
24. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
[TBL] [Abstract][Full Text] [Related]
25. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Sakhdari A; Tang Z; Ok CY; Bueso-Ramos CE; Medeiros LJ; Huh YO
Cancer Genet; 2019 Oct; 238():18-22. PubMed ID: 31425921
[TBL] [Abstract][Full Text] [Related]
26. CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia and is distinctly low in KMT2A-rearranged cases.
Collins K; Cardinali JL; Mnayer LO; DiGiuseppe JA
Cytometry B Clin Cytom; 2021 Mar; 100(2):243-248. PubMed ID: 31894899
[TBL] [Abstract][Full Text] [Related]
27. Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival.
Tong J; Zhang L; Liu H; Xu X; Zheng C; Yao W; Zhu X; Tang B; Wan X; Song K; Zhang X; Sun G; Sun Z
Ann Hematol; 2021 May; 100(5):1303-1309. PubMed ID: 33469688
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring
Jiang B; Zhao Y; Luo Y; Yu J; Chen Y; Ye B; Fu H; Lai X; Liu L; Ye Y; Zheng W; Sun J; He J; Zhao Y; Wei G; Cai Z; Huang H; Shi J
Cell Transplant; 2024; 33():9636897231225821. PubMed ID: 38270130
[No Abstract] [Full Text] [Related]
29. FISH improves risk stratification in acute leukemia by identifying KMT2A abnormal copy number and rearrangements.
Li Q; Xing S; Zhang H; Mao X; Xiao M; Wang Y
Sci Rep; 2022 Jun; 12(1):9585. PubMed ID: 35688861
[TBL] [Abstract][Full Text] [Related]
30. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
[TBL] [Abstract][Full Text] [Related]
31. A New Complex Karyotype Involving a KMT2A-r Variant Three-Way Translocation in a Rare Clinical Presentation of a Pediatric Patient with Acute Myeloid Leukemia.
Capela de Matos RR; Ney Garcia DR; Othman MAK; Moura Ferreira G; Melo JB; Carreira IM; Meyer C; Marschalek R; Costa ES; Land MGP; Liehr T; Ribeiro RC; Silva MLM
Cytogenet Genome Res; 2019; 157(4):213-219. PubMed ID: 30974445
[TBL] [Abstract][Full Text] [Related]
32. Myeloid sarcoma is associated with poor clinical outcome in pediatric patients with acute myeloid leukemia.
Xu LH; Wang Y; Chen ZY; Fang JP
J Cancer Res Clin Oncol; 2020 Apr; 146(4):1011-1020. PubMed ID: 31919567
[TBL] [Abstract][Full Text] [Related]
33. The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
Liu XX; Pan XA; Gao MG; Kong J; Jiang H; Chang YJ; Zhang XH; Wang Y; Liu KY; Chen Z; Zhao XS; Huang XJ
Int J Lab Hematol; 2023 Apr; 45(2):195-203. PubMed ID: 36358022
[TBL] [Abstract][Full Text] [Related]
34. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
[TBL] [Abstract][Full Text] [Related]
35. Droplet Digital PCR for Oncogenic KMT2A Fusion Detection.
Young AL; Davis HC; Challen GA
J Mol Diagn; 2023 Dec; 25(12):898-906. PubMed ID: 37813299
[TBL] [Abstract][Full Text] [Related]
36. Adult Acute Myeloid Leukemia with the KMT2A-Mixed Lineage Leukemia T10 Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway.
Cai X; Wang J; Lu J; Jia Z; Chen M; Liu J; Lu X; Chao H
Acta Haematol; 2022; 145(2):144-151. PubMed ID: 34551411
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
[TBL] [Abstract][Full Text] [Related]
38. PAX5 alterations in an infant case of KMT2A-rearranged leukemia with lineage switch.
Nakajima K; Kubota H; Kato I; Isobe K; Ueno H; Kozuki K; Tanaka K; Kawabata N; Mikami T; Tamefusa K; Nishiuchi R; Saida S; Umeda K; Hiramatsu H; Adachi S; Takita J
Cancer Sci; 2022 Jul; 113(7):2472-2476. PubMed ID: 35467057
[TBL] [Abstract][Full Text] [Related]
39. Haploidentical peripheral blood stem cell transplantation without irradiation or busulfan after reduced-intensity conditioning for KMT2A(MLL)-rearranged infant B-cell precursor acute lymphoblastic leukemia: Report of two cases.
Yoshimi A; Kato K; Hosaka S; Suzuki R; Fukushima H; Nakao T; Kobayashi C; Fukushima T; Koike K; Sumazaki R; Tsuchida M
Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28332262
[TBL] [Abstract][Full Text] [Related]
40. Enhancer-activated RET confers protection against oxidative stress to KMT2A-rearranged acute myeloid leukemia.
Frett B; Stephens KE; Koss B; Melnyk S; Farrar J; Saha D; Roy Choudhury S
Cancer Sci; 2024 Mar; 115(3):963-973. PubMed ID: 38226414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
